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Background: The aim of this study was to investigate whether carbon-ion beam irradiation 
in combination with 5-fluorouracil (5-FU) is superior to carbon-ion beam irradiation alone in 
targeting colorectal cancer stem-like cells (CSCs).
Materials and Methods: Human colorectal cancer (CRC) cells, HCT116 and HT29, were 
treated with carbon-ion beam irradiation alone or in combination with 5-FU. Cell viability 
assay, colony and spheroid formation assay, apoptotic assay, and quantitative real-time PCR 
analysis of apoptosis- and autophagy-related gene expression were performed.
Results: Carbon-ion beam irradiation dose-dependently decreased CRC cell viability and 
showed significantly enhanced cell killing effect when combined with 5-FU. Carbon-ion 
beam irradiation in combination with 5-FU significantly increased the percentage of apopto-
tic cells. The expression of some apoptotic and autophagy-related genes such as Bax, Bcl2, 
Beclin1 and ATG7 was significantly induced by carbon-ion beam irradiation alone and was 
further enhanced when the beam was combined with 5-FU. The spheroid forming capacity of 
CD133+ cell subpopulations was significantly inhibited by carbon-ion beam in combination 
with 5-FU. Histopathologically, the combination of carbon-ion beam irradiation and 5-FU 
destroyed more xenograft tumor cells, and resulted in increased necrosis, cavitation, and 
fibrosis, compared to carbon-ion beam irradiation alone.
Conclusion: In conclusion, carbon-ion beam treatment combined with 5-FU has the poten-
tial to kill CRC cells including CSCs by inducing increased apoptosis and autophagy.
Keywords: colorectal cancer stem cell, heavy ion radiation, 5-FU
Introduction
Colorectal cancer (CRC) is the most common gastrointestinal cancer and the second 
leading cause of cancer-related death in Korea and Japan.1,2 Surgical resection is the 
primary treatment for CRC. However, patients have a higher recurrence rate if the 
primary tumor has penetrated the serosa or if local lymph node metastases are present at 
the time of surgery.3–6 In fact, a high percentage of locally recurrent rectal carcinoma 
show bone or vessel infiltration in the pelvis, which make surgical resection difficult.
Locally recurrent CRCs are generally radioresistant as they contain large number of 
hypoxic cells, and it is difficult to elevate the radiation dose due to the proximity to 
nearby radiosensitive organs, including the colon, bladder, and small intestine.7,8 
Therefore, an effective combination therapy to eradicate radioresistant tumor cells is 
urgently needed.9,10 Combination of radiation therapy and 5-fluorouracil (5-FU) treat-
ment has been shown to improve the outcome in advanced CRC.11–13 Recently, the 
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prognosis for metastatic or unresectable CRC has improved 
owing to the approval of 5-FU for advanced CRC.14,15 
Meanwhile, a small population of colorectal cancer stem 
cells (CSCs) was identified on the basis of the cell membrane 
markers CD133 +, CD44 +, ESA + cells.16,17 CSCs are 
closely correlated with tumor recurrence, metastasis and 
chemoradioresistance.18–20 Therefore, developing more 
effective therapies to eliminate CSC is crucial.21–26
Based on high local control rate and increased induc-
tion of unrepairable clustered DNA damage, we success-
fully treated more than 13,000 patients with various tumor 
types, including more than 600 patients with postoperative 
recurrent CRC using carbon-ion radiotherapy (CIRT) over 
the past 26 years and have achieved encouraging 
outcomes.27–29 However, limiting dose escalation in 
cases where the tumor is very close to important organs 
or with invisible micrometastases is one of the most 
important challenges with CIRT. Therefore, carbon-ion 
beam irradiation in combination with the DNA damaging 
agent 5-FU not only has the potential to destroy radio-
resistant CSCs but can also reduce the radiation dose 
required, and still destroy CRC.
Recently, it has been reported that carbon-ion beam 
irradiation alone can effectively kill colorectal and pancrea-
tic CSCs, and when combined with DNA damaging agents 
such as gemcitabine,cisplatin, tyrosine kinase inhibitor such 
as lapatinib, and bisphosphonate such as zoledronic acid are 
more potent in killing various cancer cells including CSCs 
compared to carbon-ion beam irradiation alone.30–36 In the 
current study, we investigated the effect of carbon-ion beam 
irradiation in combination with the DNA damaging agent 
5-FU, on CRC viability, colony and spheroid formation 
ability of CSCs, and changes in the expression of cell death- 
related genes. To the best of our knowledge, this is the first 
study to demonstrate that carbon-ion beam irradiation in 
combination with 5-FU is more effective in targeting color-
ectal CSCs compared to carbon-ion beam irradiation alone.
Materials and Methods
Cell Lines
Colon adenocarcinoma cell lines HCT116 and HT29 were 
originally obtained from the American Type Culture 
Collection (Manassas, VA, USA). Cells were cultured in 
Dulbecco’s Modified Eagle Medium (Invitrogen, Grand 
Island, NY) supplemented with 10% fetal bovine serum 
(FBS, Beit-Haemek, Kibbutz Beit Haemek, Israel) at 37°C 
with 5% CO2. The medium was changed twice a week.
Irradiation
High linear energy transfer (LET) carbon-ion beams produced 
by the heavy ion medical accelerator in Chiba (HIMAC) were 
used to irradiate cells or mice. Detailed descriptions about the 
characteristics of the carbon-ion beams, the biological irradia-
tion procedure, and dosimetry have been described 
previously.27 In brief, a 290 MeV/u carbon-ion beam with 
a 6 cm spread-out Bragg peak (SOBP) at the center (50 keV/ 
μm) was used. As a reference, the cells or mice were also 
irradiated with conventional 200 kVp X-ray (TITAN-320, GE, 
Lewistown, PA, USA).
Cell Viability Assay
CellTiter-Glo Luminescent Cell Viability Assay (Promega, 
Madison, WI, USA) or WST-1 Cell Proliferation Assay 
(Roche, Mannheim, Germany) was used for cell viability 
analysis. The CellTiter-Glo® Luminescent Cell Viability 
Assay is a standard method for determining the number of 
viable cells in culture based on the quantification of ATP 
present, which is indicative of metabolically active cells. 
The CellTiter-Glo® Assay is ideal for cell proliferation and 
cytotoxicity assays performed by automated, high- 
throughput screening in a multi-well plate format. In the 
homogeneous assay procedure, a single reagent (CellTiter- 
Glo® Reagent) is added directly to cells grown in serum- 
supplemented medium. WST-1 Cell Proliferation Assay is 
a colorimetric analysis of formazan formation in living 
cells based on the cleavage of the tetrazolium salt WST-1 
by mitochondrial dehydrogenase.
CSC Assays
Clonogenic and spheroid formation assays were performed 
with the previously established methods30 that using cells 
sorted from HCT116 cells. The sorted CD133+ and CD44 
+/ESA+ cell subpopulations were resuspended at a cell 
density of 500 or 2000 cells/mL and plated in triplicate in 
6 cm dishes or 96-well spheroid formation plates (Sumilon, 
Sumitomo Bakelite Co., Ltd, Tokyo, Japan). After allowing 
the cells to grow for 1–2 weeks, the percentage of colonies 
or spheres per well was calculated and expressed as the 
percentage of wells containing colonies or spheres.
Analysis of Apoptosis Using Flow 
Cytometry
Apoptosis was analyzed using flow cytometry with the 
Annexin V-FITC Apoptosis Detection Kits (R&D 
Systems, Minneapolis, MN USA) according to the 
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manufacturer’s protocol. Briefly, irradiated cells were har-
vested after 96 h by trypsinization, washed with PBS, and 
apoptotic and necrotic cells were analyzed following the 
addition of 100 μL binding buffer and 1 μL fluorescently 
labeled Annexin V-FITC in each sample. The samples 
were mixed gently and incubated at room temperature in 
the dark for 15 min. Immediately prior to the analysis by 
flow cytometry (BD FACSCalibur Flow Cytometry 
System), 1 µL of propidium iodide (PI, 1 mg/mL; 
Cedarlane Laboratories, Hornby, Ontario, Canada) was 
added to each sample. A minimum of 10,000 cells were 
analyzed in the gated area.
Real-Time RT-PCR Analysis of Expression 
of Various Genes Related to Apoptosis 
and Autophagy
RNA was extracted using the Qiagen RNeasy kit following 
on-column DNAse treatment to remove genomic DNA. 
cDNA was reverse transcribed using the RT2 First Strand 
Kit (SABiosciences, Frederick, Maryland, USA). 
Apoptotic- and autophagy-related gene expression was 
analyzed using real-time RT-PCR on a LightCycler® 96 
system (Roche, Basel, Switzerland). Data analysis was 
performed by applying the ΔΔCt method using the RT- 
PCR software package (n = 3).31,32 The primer sequences 
used in the PCR are shown in Table 1. GAPDH was used 
as a housekeeping gene.
Histopathological Analysis of Xenograft 
Tumor Following Carbon-Ion Beam 
Irradiation Alone or in Combination with 
5-FU
NOD/SCID mice (male, 6–8 weeks old, Charles River 
Laboratories, Japan) were housed under conditions 
defined in the National Institutes for Quantum and 
Radiological Science and Technology (QST)-National 
Institute of Radiological Sciences (NIRS) animal facil-
ity. HCT116 cells were injected in the right legs of the 
NOD-SCID mice, and the mice were treated with car-
bon-ion beam alone or in combination with 5-FU once 
the xenograft tumors reached approximately10 mm in 
diameter. Following carbon-ion beam irradiation, 5-FU 
was administered through intraperitoneal injection (I.P) 
twice a week for 2 weeks. Mice were sacrificed at 
designated time intervals (4–10 weeks) after treatment 
with carbon-ion beam irradiation alone or in 
combination with 5-FU. Tissues were fixed in formal-
dehyde and histopathologically analyzed using hema-
toxylin and eosin (HE) staining. All the animal 
experiments were conducted in or accordance with the 
QST-NIRS Institutional Animal Welfare Guidelines and 
were approved by the Institutional Animal Care and 
Use Committee of QST (Approval number:19–2006).
Statistical Analysis
StatView software (SAS Institute, Inc., Cary, NC, USA) 
was used to perform one-way analysis of variance and 
Bonferroni’s multiple comparisons test for differences in 
the mean between groups. p<0.05 was considered signifi-
cant in all comparisons.
Results
Cell Viability Following Treatment with 
Different Concentration of 5-FU
To examine the cytotoxicity of 5-FU in HCT116 and 
HT29 cells, the cells were treated with different concen-
trations of 5-FU for different time points, then the cell 
viability was determined using WST-1 assay and 
CellTiter-Glo® luminescent cell viability assay. We 
found that there was no significant dose-dependent 




















Forward 5ʹ- GCTG CTACTTC TGCAATGATGT −3ʹ
Reverse 5ʹ- GCAAGCTCACTAGG CTGCAGAACC-3’
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effect at 24 h, but cell viability was significantly 
decreased 48 and 72 h after treatment with 5-FU 
(Figure 1A).
Cell Viability Following Treatment with 
Carbon-Ion Beam Alone or in 
Combination with 5-FU
To determine radiosensitizing effects of 5-FU in 
HCT116 and HT29 cells, the cells were irradiated with 
carbon-ion beam alone or in combination with 5-FU, 
and cell viability was analyzed using CellTiter-Glo® 
luminescent cell viability assay. As shown in Figure 
1B, cell viability of both HCT116 and HT29 cells was 
reduced following treatment with carbon-ion beam and 
5-FU treatment alone, and further reduced following 
combination treatment.
Apoptosis Induction Following 
Carbon-Ion Beam Irradiation Alone or in 
Combination with 5-FU
To examine apoptosis induction in HCT116 and HT29 cells 
following carbon-ion beam irradiation alone or in combina-
tion with 5-FU. FACS analysis was performed using 
AnnexinV-FITC/PI detection kit. As shown in Figure 2, 
carbon-ion beam irradiation significantly enhanced early 
and total apoptosis in a dose-dependent manner, which was 
markedly increased when the irradiation was combined with 
5-FU in HCT116 (Figure 2A) and HT29 cells (Figure 2B).
Figure 1 (A) Viability of HCT116 and HT29 cells treated with different concentration of 5-FU (2.5, 5, 10, and 15 15 µM)) for 48 h was determined by WST-1 assay. (B) 
Viability of HCT116 and HT29 cells treated with carbon-ion beam irradiation alone or in combination with 5-FU for 96 h was determined by CellTiter-Glo® Luminescent 
Cell Viability Assay. *, p<0.01 compared to control.
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CSC Characteristics of CD133+ and 
CD44+/ESA+ Cells Sorted from HCT116
The CSC properties of CD133+ and CD44+/ESA+ cells 
were confirmed using the same method described 
previously.27 Representative immunofluorescence stained 
CSCs (CD133+ and CD44+/ESA+ cells) were shown in 
Figure 3A. Following plating of equal number of cells (500 
cells), CD133+ and CD44+/ESA+ cells sorted from HCT116 
formed significantly higher number of colonies (Figure 3B) 
and large-sized spheres (Figure 3C) compared to that formed 
from CD133- and CD44-/ESA- cells (p<0.01). The in vivo 
tumorigenicity assay showed that only CD133+ and CD44 
+/ESA+ cells formed tumors, whereas CD133- and CD44-/ 
ESA- cells did not form tumors when subcutaneously 
injected to NOD-SCID mice (Figure 3D).
Spheroid Forming Ability of CD133+ and 
CD44+/ESA+ Cells Derived from 
HCT116 and HT29 Cells Treated with 
Carbon-Ion Beam, X-Ray Alone or in 
Combination with 5-FU
The number of colonies was markedly reduced when car-
bon-ion beam irradiation was combined with 5-FU 
compared to when cells were treated with carbon-ion 
beam alone or X-ray combined with 5-FU (Figure 3E). 
We also examined the ability of CSC (CD133+, CD44 
+/ESA+) and non-CSCs (CD133-, CD44-/ESA-) to form 
spheroids following carbon-ion beam irradiation alone or 
in combination with 5-FU. As shown in Figure 3E, the size 
of spheroids formed in CSCs sorted from HCT116 and 
HT29 cells was significantly reduced following treatment 
with carbon-ion beam irradiation alone and was signifi-
cantly further reduced when carbon-ion beam was com-
bined with 5-FU. In contrast, a small size of sphere formed 
in non-CSCs has shrunk significantly following treatment 
with carbon-ion beam irradiation alone and was enor-
mously reduced following combination treatment with 
carbon-ion irradiation and 5-FU.
Changes in the Expression of Multiple 
Genes Following Carbon-Ion Beam, 
X-Ray Irradiation Alone or in 
Combination with 5-FU
To examine and compare the changes in the expression of 
multiple genes, the unsorted HCT116 cells were irradiated 
with carbon-ion beam or X-ray alone or in combination 
Figure 2 Induction of apoptosis in HCT116 (A) and HT29 (B) cells treated with carbon-ion beam irradiation alone or in combination with 5-FU for 96 h. Apoptosis was 
detected by Annexin-PI kit using FACS analysis. *, p<0.01 compared to control.
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Figure 3 (A) Representative immunofluorescence staining of CD133+, CD44+, and ESA+ cells in HCT116. (B) Colony formation of CD133+, CD44+/ESA+ and CD133-, 
CD44-/ESA- cells isolated from HCT116. (C) Spheroid formation of CD133+, CD44+/ESA+ and CD133-, CD44-/ESA- cells isolated from HCT116. (D) Tumorigenicity of 
CD133+, CD44+/ESA+ and CD133-, CD44-/ESA- cells isolated from HCT116. Histopathological features of xenograft tumor were showed. Dotted circle indicates tumor 
vessels (red blood cells were seen). (E) Spheroid forming ability after carbon-ion beam irradiation alone, or in combination with 5-FU. *, p<0.01 compared to control.
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with 5-FU. As shown in Figure 4A, carbon-ion beam 
irradiation significantly increased the expression of the 
apoptosis-related genes, Bax and Bcl2, compared to 
X-ray irradiation, and the expression was further increased 
when the carbon-ion beam was combined with 5-FU in 
HCT116 cells. Expression of autophagy-related genes, 
including Beclin1 and ATG7, but not LC3, was signifi-
cantly enhanced following carbon-ion beam irradiation 
compared to X-ray irradiation, and further augmented 
when the carbon-ion beam was combination with 5-FU 
(Figure 4A). The changes in the expression of multiple 
genes in CSCs and non-CSCs were also examined when 
treated with carbon-ion beam irradiation alone or in com-
bination with 5-FU. Interestingly, the expression of apop-
tosis-related gene, Bax was significantly increased after 
treatment with carbon-ion beam irradiation alone, and 
further increased when carbon-ion beam irradiation was 
combined with 5-FU in non-CSCs, but not in CSCs 
(Figure 4B). In comparison, Bcl2 expression was signifi-
cantly increased after treatment with carbon-ion beam 
irradiation alone, and further increased when carbon-ion 
beam irradiation was combined with 5-FU in CSCs, but 
not in non-CSCs. Expression of autophagy-related genes, 
Beclin1, LC3, and ATG7, was significantly enhanced after 
treatment with combination of carbon-ion beam irradiation 
and 5-FU in both non-CSCs and CSCs, and especially 
expression of Beclin1 and ATG7 was enormously 
increased in non-CSCs (Figure 4B).
Histopathological Changes in Xenograft 
Tumor Following Carbon-Ion Beam 
Alone or in Combination with 5-FU
To investigate the histopathological changes in HCT116 
xenograft tumors in vivo following carbon-ion beam irra-
diation alone or in combination with 5-FU, the tissues 
were stained with hematoxylin and eosin (HE). HE analy-
sis revealed that the tumor cells were markedly affected 
when irradiation with 25 Gy of carbon-ion beam combined 
with 50 mg/kg 5-FU administered i.p accompanied with 
necrosis, cavitation and fibrosis compared to irradiation 
with 30 Gy of carbon-ion beam alone or 5-FU treatment 
alone (Figure 5).
Discussion
First, to clarify the cytotoxicity of 5-FU in CRC cells, 
CRC cells were treated with increasing concentrations of 
5-FU for various time points. We found that the viability 
of both HCT116 and HT29 cells was significantly 
decreased 48 and 72 h after treatment with 5-FU in a dose- 
dependent manner. To examine whether the cell killing 
mediated by 5-FU affects carbon-ion beam, CRC cells 
were treated with carbon-ion beam irradiation alone or in 
combination with 5-FU. As expected, carbon-ion beam 
irradiation significantly reduced CRC cell viability, which 
was reduced even further when treated in combination 
with 5-FU. These results are consistent with previous 
reports showing that 5-FU has radiosensitizing effects in 
many cancer types such as colorectal, pancreatic and head 
and neck cancers.37–39
It has been demonstrated that 5-FU radiosensitizes 
CRC cells accompanied with apoptosis and/or 
autophagy.37,38 In this study, we found that carbon-ion 
beam irradiation significantly enhanced apoptosis in 
a dose-dependent manner, and induction of both early 
and total apoptosis markedly increased when the irradia-
tion was combined with 5-FU in HCT116 and HT29 cells. 
This finding is partially in line with previous reports show-
ing that 5-FU induces apoptosis in gastric, breast and 
colon cancer cells.40–42 To investigate molecular mechan-
isms of cell death induced by carbon-ion beam alone or in 
combination with 5-FU, we analyzed changes in the 
expression of apoptosis- and autophagy-related genes 
using qPCR. We found that carbon-ion beam irradiation 
caused significant increase in the apoptosis-related genes, 
Bax and Bcl2 compared to X-ray irradiation which was 
increased even further when the carbon-ion beam was 
combined with 5-FU in HCT116 cells. Expression of 
autophagy-related genes, including Beclin1 and ATG7, 
but not LC3, was significantly enhanced following carbon- 
ion beam irradiation compared to X-ray irradiation and 
was further enhanced when the beam was combined with 
5-FU. Our findings are in agreement with previous reports 
that 5-FU induces not only apoptosis but also autophagy 
and that both these effects facilitate the anticancer 
effects,43–45 and consequently sensitize CRC cells to car-
bon-ion beam irradiation.
Using clonogenic assay, we previously found that CSCs 
derived from CRC cells are resistant to both X-rays and 
carbon-ion beams compared to non-CSCs.30 In this study, 
the spheroid forming capacity was used to investigate the 
effect of carbon-ion beams in combination with 5-FU on 
CSCs. Interestingly, the spheroid forming ability of CSCs 
was markedly reduced when treated with carbon-ion beam 
combined with 5-FU compared to that of carbon-ion beam 
irradiation alone or X-ray irradiation combined with 5-FU. 
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Figure 4 (A) Changes in the expression of apoptosis- and autophagy-related genes 72 h after carbon-ion beam irradiation alone or in combination with 5-FU in unsorted 
HCT116 cells. (B) Changes in the expression of apoptosis- and autophagy-related genes 5 d after carbon-ion beam irradiation (1 Gy) alone or in combination with 5-FU 
(5µM) in CSCs and non-CSCs isolated from HCT116.
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This is partially in line with our previous reports that carbon- 
ion beam combined with DNA damaging drugs can effec-
tively destroy CSCs in pancreatic cancer, breast cancer and 
malignant mesothelioma.32–34 We also analyzed the changes 
in expression of apoptosis- and autophagy-related genes in 
CSC derived spheroids and non-CSC derived spheroids fol-
lowing treatment with carbon-ion beam irradiation alone or 
in combination with 5-FU. We found that carbon-ion beam 
irradiation alone or in combination with 5-FU markedly 
increased the expression of the apoptosis-related gene, Bax, 
in non-CSC derived spheroids, whereas the expression of 
anti-apoptosis-related gene, Bcl2, was highly enhanced in 
the CSC derived spheroids, suggesting that carbon-ion 
beam irradiation alone induced apoptosis in both non-CSCs 
and CSCs, and it was more significant when carbon-ion beam 
irradiation combined with 5-FU. Interestingly, the expression 
of the autophagy-related genes, ATG7, LC3 and Beclin1was 
tremendously enhanced in non-CSCs following treatment 
with carbon-ion beam irradiation alone or in combination 
with 5-FU. Only the combination treatment of carbon-ion 
beam irradiation and 5-FU significantly increased the expres-
sion of all three genes, AGT7, LC3 and Beclin1 in CSCs, 
whereas carbon-ion beam irradiation alone did not. These 
findings imply that carbon-ion beam irradiation combined 
with 5-FU has strong potential to induce autophagy-mediated 
cell death rather than apoptosis-mediated cell death. This is 
partially consistent with previous reports that autophagic cell 
death induced by 5-FU can be used as an alternative cell 
death pathway in apoptosis defective cells.45 In addition, 
in vivo histopathological analysis of xenograft tumor showed 
that carbon-ion beam in combination with 5-FU killed tumor 
cells as evidenced by increased necrosis, cavitation and 
fibrosis compared to carbon-ion beam irradiation or 5-FU 
alone.
In summary, carbon-ion beam irradiation combined 
with 5-FU has superior effects on targeting colorectal 
CSCs accompanied with increased apoptosis, autophagy, 
and subsequent cell death compared to carbon-ion beam 
alone. Taken together, our findings imply that carbon-ion 
beam combined with 5-FU has strong potential to kill 
radioresistant CRC cells including CSCs in vitro and 
in vivo.
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